title: Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer.
abstract: OBJECTIVE
  The objective of this study was to evaluate the blood platelet-lymphocyte ratio (PLR) for its prognostic value in patients with metastatic renal cell cancer (RCC).
  
  
  METHODS
  We retrospectively reviewed 100 patients diagnosed with metastatic RCC previously treated with tyrosine kinase inhibitors from three centers. We assessed the prognostic value of pretreatment PLR and other clinical and laboratory parameters based on univariate and multivariate analyses.
  
  
  RESULTS
  Median progression-free survival (PFS) was 7.3 months and median overall survival (OS) was 15.3 months. Multivariate analysis revealed that PFS is significantly affected by ECOG PS (P = 0.047), PLR (P = 0.029) and calcium level (P = 0.023). Median PFS was 13.9 versus 5.3 months in patients with PLR ≤ 210 versus PLR > 210 (log rank; P = 0.001). Median OS was 25.9 versus 10.9 months with PLR ≤ 210 versus PLR > 210 (log rank; P = 0.013).
  
  
  CONCLUSIONS
  This study shows that increased pretreatment PLR is an independent prognostic indicator in patients with metastatic RCC who use tyrosine kinase inhibitors.
authors: Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey.
authors: Seyda
authors: S
authors: Gunduz
authors: Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey.
authors: Hasan
authors: H
authors: Mutlu
authors: Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey.
authors: Deniz
authors: D
authors: Tural
authors: Istanbul Medipol University Hospital, Istanbul, Turkey.
authors: Özcan
authors: Ö
authors: Yıldız
authors: Afyon Kocatepe University Ahmet Necdet Sezer Research and Practice Hospital, Afyon, Turkey.
authors: Mukremin
authors: M
authors: Uysal
authors: Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey.
authors: Hasan Senol
authors: HS
authors: Coskun
authors: Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey.
authors: Hakan
authors: H
authors: Bozcuk
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001792:Blood Platelets / Q000473:pathology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
keywords: metastatic renal cell carcinoma; platelet to lymphocyte ratio; prognosis